Skip to the content

pharmaceutical daily

Pharmaceuticals, Biotechnology and Life Sciences

  • HOME
  • Pharma Business
  • About us
    • Media Kit
    • Privacy Policy
  • Contact
Alkermes, Biogen get diroximel fumarate for relapsing MS NDA accepted
February 25, 2019 Off

Alkermes, Biogen get diroximel fumarate for relapsing MS NDA accepted

By Dino Mustafić

Alkermes and Biogen said the FDA will check their novel oral fumarate in development for diroximel fumarate (BIIB098), for the treatment…

Roche buys Spark Therapeutics for $4.3 billion
February 25, 2019 Off

Roche buys Spark Therapeutics for $4.3 billion

By Dino Mustafić

Roche will fully buy Spark Therapeutics at a price of $114.50 per share in an all-cash transaction, or for $4.3…

Novartis taking over responsibility of cardiovascular therapy agent TQJ230 from Akcea Therapetuics
February 25, 2019 Off

Novartis taking over responsibility of cardiovascular therapy agent TQJ230 from Akcea Therapetuics

By Dino Mustafić

Novartis will exercise its option for worldwide responsibility of TQJ230, an investigational agent for targeted cardiovascular therapy previously known as AKCEA-APO(a)-LRx, from Akcea Therapeutics, an affiliate of Ionis Pharmaceuticals.

Tahio Oncology’s Lonsurf approved as treatment of advanced gastric and GEJ cancer in the USA
February 25, 2019 Off

Tahio Oncology’s Lonsurf approved as treatment of advanced gastric and GEJ cancer in the USA

By Dino Mustafić

Taiho Oncology got aproval to have its Lonsurf as a treatment for adult patients with metastatic gastric or gastroesophageal junction adenocarcinoma in the United States.

BioMarin slashes net loss by third year over year with milestone payments and increase in sales
February 21, 2019 Off

BioMarin slashes net loss by third year over year with milestone payments and increase in sales

By Dino Mustafić

BioMarin Pharmaceutical’s net loss for 2018 decreased $39.8 million or 34%, to $77.2 million, compared to $117.0 million in 2017, in part due to increase in gross profil of million.

February 21, 2019 Off

Mallinckrodt drops futher testing of Therakos to treat young patients with Steroid Refractory Acute Graft-versus-Host Disease

By Dino Mustafić

Mallinckrodt will drop testing its Therakos in the Phase 3 clinical trial for treating young patients with Steroid Refractory Acute Graft-versus-Host Disease, after the interim results were published.

February 21, 2019 Off

Faron Pharmaceuticals opens two UK sites to expand Matins trial, testing its cancer immunotherapy Clevegen

By Dino Mustafić

Faron Pharmaceuticals said Thursday in a press release that it is currently opening two UK sites (London, Birmingham) to expand the Matins trial, following recent CTA approval by the UK regulator, the Medicines & Healthcare products Regulatory Agency (MHRA).

Torque, Merck to test Keytruda with Deep IL-15 Primed T cells
February 20, 2019 Off

Torque, Merck to test Keytruda with Deep IL-15 Primed T cells

By Dino Mustafić

Torque will test its Deep IL-15 Primed T Cells (TRQ-1501) with Merck, both as a single agent and in combination with Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, in a Phase 1/2 study in multiple solid tumor indications.

Xencor pauses testing leukemia bispecific antibody molecule as FDA inspects two possibly related deaths
February 20, 2019 Off

Xencor pauses testing leukemia bispecific antibody molecule as FDA inspects two possibly related deaths

By Dino Mustafić

Xencor has put on hold one of its studies on myeloid leukemia CD123 x CD3 bispecific antibody molecule XmAb14045, until the FDA lifts the hold, the company said Wednesday in a press release.

Alvogen launches its generic Suboxane in the US
February 20, 2019 Off

Alvogen launches its generic Suboxane in the US

By Dino Mustafić

Alvogen has launched its generic equivalent to Indivior UK LLC’s Suboxone sublingual film (buprenorphine hydrochloride/naloxone hydrochloride) in the U.S.

Posts pagination

Previous 1 … 3,363 3,364 3,365 … 3,606 Next

JOIN OUR COMMUNITY

Proudly powered by WordPress | Theme: Envo Magazine